Reports Q 3 sash and cash equivalents as of September 30 were $51M compared to $84.7M as of December 31, 2021. The Company expects current cash and cash equivalents to be sufficient to fund its planned operating and capital expenditures through early 2023.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on JSPR:
- Jasper Therapeutics initiated with a Buy at EF Hutton
- William Blair biotech analysts to hold analyst/industry webinar
- Jasper announces clinical data from invesigator sponsored study of JSP191
- Jasper Therapeutics to Present at Upcoming Conferences
- Jasper Therapeutics receives fast track designation for JSP191